Limits...
Salivary biomarkers indicate obstructive sleep apnea patients with cardiovascular diseases.

Zheng H, Li R, Zhang J, Zhou S, Ma Q, Zhou Y, Chen F, Lin J - Sci Rep (2014)

Bottom Line: In our study, eleven peaks were observed differentially expressed in saliva from the non-CVD and CVD groups.Five masses mass peaks (1594.1, 1673.7, 1196.6, 1290.5, and 1447.0 Da) showed an upregulated trend in the CVD group, whereas six mass peaks (3038.6, 2164.3, 2301.4, 3195.0, 2628.4, and 1721.9 Da) were downregulated in the CVD group.In addition, the alpha-2-HS-glycoprotein (AHSG) levels in saliva were verified to be decreased in CVD group compared to non-CVD group.

View Article: PubMed Central - PubMed

Affiliation: Department of Orthodontics, Peking University School and Hospital of Stomatology, Beijing 100081, China.

ABSTRACT
Although obstructive sleep apnea (OSA) patients are at high risk of developing cardiovascular disease (CVD), only a small proportion is currently diagnosed. To explore and identify the differentially expressed proteins/peptides of OSA patients with CVDs, a mass spectrometry-based salivary analysis was performed. In our study, eleven peaks were observed differentially expressed in saliva from the non-CVD and CVD groups. Five masses mass peaks (1594.1, 1673.7, 1196.6, 1290.5, and 1447.0 Da) showed an upregulated trend in the CVD group, whereas six mass peaks (3038.6, 2164.3, 2301.4, 3195.0, 2628.4, and 1721.9 Da) were downregulated in the CVD group. In addition, the alpha-2-HS-glycoprotein (AHSG) levels in saliva were verified to be decreased in CVD group compared to non-CVD group. Analysis of the salivary peptidome provides a promising approach to screening for novel biomarkers before further identification, and may contribute to early diagnosis of CVD patients with OSA.

Show MeSH

Related in: MedlinePlus

Differentially expressed peptides between non-CVD-OSA and CVD-OSA patients.(A) Five mass peaks showed an upregulated trend in the CVD group, and (B) six mass peaks were downregulated in the CVD group. *p < 0.05; **p < 0.01 by two-tailed Student's t-test after FDR correction.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4231342&req=5

f2: Differentially expressed peptides between non-CVD-OSA and CVD-OSA patients.(A) Five mass peaks showed an upregulated trend in the CVD group, and (B) six mass peaks were downregulated in the CVD group. *p < 0.05; **p < 0.01 by two-tailed Student's t-test after FDR correction.

Mentions: We investigated the differences between CVD-OSA and non-CVD-OSA patients to identify promising protein/peptide biomarkers for early disease prediction. The clinical characteristics of CVD patients and controls are shown in Table 1. Examples of both the raw and processed entire mass spectra of the enriched peptide samples from MALDI-TOF MS are shown in Figure 1. An average of 92 peaks ranging from 1000 to 7000 Da were detected. Of these, 39 showed a p value < 0.05 according to Student's t test and 11 with an average mass area > 300 (3038.6, 2164.3, 2301.4, 1594.1, 1673.7, 3195.0, 1196.6, 1290.5, 2628.4, 1721.9, and 1447.0 Da; Table 2). The p values remains significant after correcting for multiple comparisons using false discovery rate (FDR) correction. Of the 11 peptide masses, five masses (1594.1, 1673.7, 1196.6, 1290.5, and 1447.0 Da) showed an upregulated trend in the CVD group, whereas six potential mass peaks (3038.6, 2164.3, 2301.4, 3195.0, 2628.4, and 1721.9 Da) were downregulated in the CVD group (Figure 2). The most significant differences were exhibited by the 3038.6 and 2164.3 Da peptides (p < 0.01, both showed a decreased tendency in the CVD group; Figure 3).


Salivary biomarkers indicate obstructive sleep apnea patients with cardiovascular diseases.

Zheng H, Li R, Zhang J, Zhou S, Ma Q, Zhou Y, Chen F, Lin J - Sci Rep (2014)

Differentially expressed peptides between non-CVD-OSA and CVD-OSA patients.(A) Five mass peaks showed an upregulated trend in the CVD group, and (B) six mass peaks were downregulated in the CVD group. *p < 0.05; **p < 0.01 by two-tailed Student's t-test after FDR correction.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4231342&req=5

f2: Differentially expressed peptides between non-CVD-OSA and CVD-OSA patients.(A) Five mass peaks showed an upregulated trend in the CVD group, and (B) six mass peaks were downregulated in the CVD group. *p < 0.05; **p < 0.01 by two-tailed Student's t-test after FDR correction.
Mentions: We investigated the differences between CVD-OSA and non-CVD-OSA patients to identify promising protein/peptide biomarkers for early disease prediction. The clinical characteristics of CVD patients and controls are shown in Table 1. Examples of both the raw and processed entire mass spectra of the enriched peptide samples from MALDI-TOF MS are shown in Figure 1. An average of 92 peaks ranging from 1000 to 7000 Da were detected. Of these, 39 showed a p value < 0.05 according to Student's t test and 11 with an average mass area > 300 (3038.6, 2164.3, 2301.4, 1594.1, 1673.7, 3195.0, 1196.6, 1290.5, 2628.4, 1721.9, and 1447.0 Da; Table 2). The p values remains significant after correcting for multiple comparisons using false discovery rate (FDR) correction. Of the 11 peptide masses, five masses (1594.1, 1673.7, 1196.6, 1290.5, and 1447.0 Da) showed an upregulated trend in the CVD group, whereas six potential mass peaks (3038.6, 2164.3, 2301.4, 3195.0, 2628.4, and 1721.9 Da) were downregulated in the CVD group (Figure 2). The most significant differences were exhibited by the 3038.6 and 2164.3 Da peptides (p < 0.01, both showed a decreased tendency in the CVD group; Figure 3).

Bottom Line: In our study, eleven peaks were observed differentially expressed in saliva from the non-CVD and CVD groups.Five masses mass peaks (1594.1, 1673.7, 1196.6, 1290.5, and 1447.0 Da) showed an upregulated trend in the CVD group, whereas six mass peaks (3038.6, 2164.3, 2301.4, 3195.0, 2628.4, and 1721.9 Da) were downregulated in the CVD group.In addition, the alpha-2-HS-glycoprotein (AHSG) levels in saliva were verified to be decreased in CVD group compared to non-CVD group.

View Article: PubMed Central - PubMed

Affiliation: Department of Orthodontics, Peking University School and Hospital of Stomatology, Beijing 100081, China.

ABSTRACT
Although obstructive sleep apnea (OSA) patients are at high risk of developing cardiovascular disease (CVD), only a small proportion is currently diagnosed. To explore and identify the differentially expressed proteins/peptides of OSA patients with CVDs, a mass spectrometry-based salivary analysis was performed. In our study, eleven peaks were observed differentially expressed in saliva from the non-CVD and CVD groups. Five masses mass peaks (1594.1, 1673.7, 1196.6, 1290.5, and 1447.0 Da) showed an upregulated trend in the CVD group, whereas six mass peaks (3038.6, 2164.3, 2301.4, 3195.0, 2628.4, and 1721.9 Da) were downregulated in the CVD group. In addition, the alpha-2-HS-glycoprotein (AHSG) levels in saliva were verified to be decreased in CVD group compared to non-CVD group. Analysis of the salivary peptidome provides a promising approach to screening for novel biomarkers before further identification, and may contribute to early diagnosis of CVD patients with OSA.

Show MeSH
Related in: MedlinePlus